Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign
If you were developing a new antibiotic with a novel MoA, one that covers most GPC, most GNR, most anaerobes and atypicals, including many MDR pathogens like MRSA, enterococci (both E. faecalis and E. faecium), and one that has also Continue reading Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign